Table 2.

Treatment outcomes of switching from ranibizumab to aflibercept.

Eyes with a dry macula (n)
before treatment	0 (0.0%)
after ranibizumab, before switching	0 (0.0%)
after first aflibercept injection	5 (35.7%)
after second aflibercept injection	7 (50.0%)
after third aflibercept injection	8 (57.1%)
Maximum subretinal fluid thickness (µm)
before treatment	134 ± 66 (55–261)
after ranibizumab, before switching	102 ± 48 (44–210)
after first aflibercept injection	49 ± 53 (0–157)
after second aflibercept injection	39 ± 52 (0–164)
after third aflibercept injection	39 ± 62 (0–173)
Maximum subfoveal choroidal thickness (µm)
before treatment	333 ± 99 (274–542)
after ranibizumab, before switching	302 ± 82 (182–514)
after first aflibercept injection	282 ± 89 (137–470)
after second aflibercept injection	269 ± 86 (139–442)
after third aflibercept injection	269 ± 93 (134–447)
Maximum central subfield thickness (µm)
before treatment	372 ± 74 (253–556)
after ranibizumab, before switching	327 ± 78 (252–545)
after first aflibercept injection	285 ± 103 (181–573)
after second aflibercept injection	277 ± 92 (185–532)
after third aflibercept injection	285 ± 98 (203–556)
Visual acuity (logMAR)
before treatment	0.6 ± 0.4 (0.1–1.1)
after ranibizumab, before switching	0.5 ± 0.3 (0.1–1.3)
after first aflibercept injection	0.4 ± 0.3 (0.0–1.3)
after second aflibercept injection	0.5 ± 0.3 (0.0–1.3)
after third aflibercept injection	0.4 ± 0.3 (0.0–1.2)